Concentrix Corporation Form 8-K Summary
Business Context and Reporting Period
Concentrix Corporation filed this Form 8-K on January 20, 2021, with the report signed on January 22, 2021. The filing concerns executive equity awards following the company’s separation from SYNNEX Corporation, completed on December 1, 2020.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating and financial performance metrics.
Material Changes and Executive Compensation
- Restricted stock awards were granted to Chief Financial Officer Andre Valentine, Executive Vice President of Global Operations and Delivery Cormac Twomey, Executive Vice President of Global Sales and Account Management Richard Rosso, and Executive Vice President of Legal Steven Richie.
- Valentine, Twomey, and Rosso each received 16,705 restricted shares. Richie received 14,617 restricted shares.
- These awards vest in equal installments on each of the first four anniversaries of October 7, 2020.
- Chief Executive Officer Chris Caldwell received 4,594 restricted shares vesting in equal installments over five years from October 7, 2020.
- Caldwell also received 83,528 restricted shares vesting in equal installments over five years from December 1, 2020.
- Caldwell received an option to purchase 26,212 shares at an exercise price of $119.72. The option vests 20% on October 7, 2021, with the remainder vesting ratably monthly over the following 48 months.
Outlook, Risks, and Unusual Items
The filing contains no financial guidance or business outlook. The awards were described as part of the company’s 2020 employee equity awards and as recognition of the successful separation from SYNNEX. The filing does not disclose the fair value, accounting expense, performance conditions, or expected dilution associated with the awards.
Important Facts to Verify
- Review Exhibits 10.1 and 10.2 for the complete restricted stock and stock option terms.
- Verify the accounting fair value and expense recognition for the awards in subsequent financial statements.
- Assess the potential dilution from the 156,? Wait total shares. Need calculate: 16705*3=50115 +14617=64732 +4594+83528+26212 option = 179066. Avoid typo. Use exact.
- Assess potential dilution from 179,066 shares underlying the disclosed restricted stock awards and stock option, subject to applicable award terms.
- Confirm vesting dates, forfeiture provisions, and the option’s exercise price in the underlying agreements.